Rationale for metronomic chemotherapy in phase III trials
Authors:
- 12 May 2015
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 12 (6) , 313-314
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer GroupThe Lancet, 2015
- Progress in defining first-line and maintenance therapiesNature Reviews Clinical Oncology, 2015
- Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialThe Lancet Oncology, 2013
- Why Do Phase III Clinical Trials in Oncology Fail so Often?JNCI: Journal of the National Cancer Institute, 2012
- Mouse models of advanced spontaneous metastasis for experimental therapeuticsNature Reviews Cancer, 2011
- Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 2010
- A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of CancerJournal of Clinical Oncology, 2005
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.2000